Loading...
•
Dec 31, 2023
Nevro Q4 2023 Earnings Report
Nevro's Q4 2023 performance reflected continued execution of its three-pillar strategy.
Key Takeaways
Nevro Corp. reported a 2% increase in worldwide revenue, reaching $116.2 million in Q4 2023. Painful Diabetic Neuropathy (PDN) Indication sales increased by 29% to $22.4 million. The company's net loss from operations was $11.8 million, while adjusted EBITDA was $8.4 million.
Worldwide revenue grew to $116.2 million, a 2% increase year-over-year.
Painful Diabetic Neuropathy (PDN) Indication sales increased 29% to approximately $22.4 million.
U.S. trial procedures decreased approximately 1%, in line with expectations; U.S. PDN trial procedures were 24% of total U.S. trials.
Net loss from operations was $11.8 million; adjusted EBITDA was $8.4 million.
Revenue by Geographic Location
Forward Guidance
Nevro expects full-year 2024 revenue to be in the range of $435 million to $445 million, representing 2% to 5% growth. First-quarter 2024 revenue is expected to be in the range of $97 million to $99 million, a 1% to 3% growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...